Jorge Castillo, MD
Hematology & Oncology · Boston, MANPI 1689891129
Payments from drug & device makers
Across 480 payments — averaging $65,015 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$10.5M
- Pharmacyclics LLC, An Abbvie Company$10.3M
- Beigene, Ltd.$5.9M
- AstraZeneca$2.8M
- Beone Medicines Ltd.$641K
- Janssen Research & Development, LLC$438K
- plus $647K from 16 others
Across 3 payments — averaging $256,887 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$768K
- Pharmacyclics LLC, An Abbvie Company$3K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 66 | $10,483,252 |
| Pharmacyclics LLC, An Abbvie Company | 60 | $10,302,711 |
| Beigene, Ltd. | 196 | $5,940,445 |
| AstraZeneca | 9 | $2,755,155 |
| Beone Medicines Ltd. | 20 | $641,370 |
| Janssen Research & Development, LLC | 15 | $437,734 |
| E.r. Squibb & Sons, L.L.C. | 2 | $358,085 |
| Eli Lilly | 2 | $194,209 |
| Beigene USA, Inc. | 55 | $57,604 |
| Johnson & Johnson | 13 | $9,035 |
| Beigene Switzerland GmbH | 8 | $8,376 |
| Beone Medicines USA, Inc. | 11 | $7,865 |
| Amgen | 2 | $3,750 |
| Lilly USA, LLC | 1 | $3,600 |
| Gilead | 3 | $2,707 |
| Sanofi | 6 | $569 |
| Lantheus Medical Imaging, Inc. | 1 | $490 |
| Abbott | 6 | $133 |
| Recordati_rare_diseases_inc. | 1 | $84 |
| Neotract Inc. | 1 | $78 |
| Genmab U.S., Inc. | 1 | $60 |
| Sobi, Inc | 1 | $55 |
How this compares
$31,207,365 in reported general payments places this provider in the 95th percentile of 374 hematology & oncology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Boston
- Matthew DavidsBoston$58.6M
- Nadine TungBoston$32.4M
- Daniel DeangeloBoston$28.5M
- Sara TolaneyBoston$20.3M
- Paul RichardsonBoston$17.2M
- Amir FathiBoston$14.8M
- Jacqueline GarciaBoston$13.6M
- John KorethBoston$12.8M
- David ReardonBoston$12M
- Panagiotis KonstantinopoulosBoston$11.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.